For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Attruby represents a significant change. These groundbreaking therapies protect the transthyretin protein, halting its destructive build-up and alleviating the severity of the condition . Individuals are now reporting impr